Dr. David Johnson highlights some of the most interesting and intriguing topics to be presented at this year's Digestive Disease Week (DDW) meeting in Chicago.

Dr. Paul Sax considers how the high cost of sofosbuvir, simeprevir, and other potentially curative agents might affect their use in patients with HCV genotype 1 infection.

Dr. David Kerr reports on a well-conducted, 10-year study showing no benefit in the use of adjuvant chemotherapy in rectal patients, but he's not ready to stop using adjuvant chemo in his patients.

George Lundberg uses an 11-item scorecard to compare the efficiency, cost-effectiveness, and populism of US healthcare and the US Postal Service.

What will physician and patient interactions look like in the near future? Medscape Editor-in-Chief Eric Topol, MD, talks about how technology is changing the practice of medicine.

Dr. David Johnson reviews new data that put to rest several long-held beliefs about diverticulosis and diverticulitis.

What effect does reinfection with hepatitis C have on our ability to control the epidemic we are faced with?

What code of conduct applies to a physician who becomes a politician, journalist, or TV personality hawking medical miracles?

Drs. Paul Sax and David Thomas reflect on how the worlds of gastroenterology and infectious disease have joined to meet the need for fast-paced guidance in hepatitis C treatment.

Dr. John Marshall found board certification 'really hard,' partly because questions had no right answer. He asks: Are boards a fair measure of a practicing physician's skills and knowledge base?